Compare TG Therapeutics Inc (TGTX) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Verisign, Inc. — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while Verisign, Inc. trades at $288.99 (market cap $26.00B). The key difference: Verisign, Inc. is far larger — about 3.4× TG Therapeutics Inc's market cap, and Verisign, Inc. pays a 1.13% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | VRSN | |
|---|---|---|
Market Cap | $7.64B | $26.00B |
Sector | Health | Technology |
52-Week High | $59.06 | $310.00 |
52-Week Low | $26.94 | $211.49 |
Enterprise Value | $7.84B | $27.31B |
Dividend Yield | — | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
VeriSign (VRSN) trades at $282.94, down 3.55% over the past day, with a mixed earnings history including a recent Q2 2026 EPS miss. The stock shows a bullish technical trend with strong moving averages, while fundamentals highlight robust profitability with a net income margin near 50% and revenue growth to $1.66B in 2025. Recent news emphasizes record domain registrations and the delegation of the .web domain, supporting growth outlook.
The outlook remains positive with a consensus price target of $320, reflecting 13% upside, driven by AI-fueled domain demand and pricing power. Risks include contract renewals and high debt levels, but analyst sentiment is bullish with 60% buy ratings. The stock presents a growth opportunity with manageable execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
